Dr. Landovitz is chief of the Division of Infectious Diseases in the Department of Medicine at the David Geffen School of Medicine, University of California, Los Angeles. He also serves as the director of the UCLA Center for Clinical AIDS Research and Education (CARE) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). As one of the protocol chairs for HPTN 077 and HPTN 083, Dr. Landovitz helped lead the NIH-funded trials that supported the 2021 FDA approval of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP).

Dr. Sybil Hosek, protocol chair for HPTN 083-01 and HPTN 084-01, is a clinical adolescent psychologist at Stroger Hospital of Cook County and an assistant professor in the Division of Infectious Disease at Rush University in Chicago. Her research interests are focused on HIV prevention among adolescents and young adults.  

Dr. Sinead Delany-Moretlwe serves as the research director at Wits RHI in Johannesburg, South Africa, and is a professor of global health and infectious diseases at the University of the Witwatersrand in Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases, particularly in adolescent girls and young women (AGYW). She served as the protocol chair of HPTN 084 and assumed the role of co-principal investigator of the HIV Prevention Trials Network (HPTN) in December 2025.